TCGA-EW-A1P4-01A-21R-A144-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 30
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.560
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.540
- IL6_JAK_STAT3_SIGNALING+0.480
- INFLAMMATORY_RESPONSE+0.460
- TNFA_SIGNALING_VIA_NFKB+0.460
- INTERFERON_GAMMA_RESPONSE+0.450
- MYC_TARGETS_V2+0.440
- MTORC1_SIGNALING+0.410
- MYC_TARGETS_V1+0.400
Top 10 suppressed
- PROTEIN_SECRETION-0.240
- BILE_ACID_METABOLISM-0.190
- ESTROGEN_RESPONSE_EARLY-0.170
- PEROXISOME-0.140
- HEME_METABOLISM-0.100
- HEDGEHOG_SIGNALING-0.090
- ADIPOGENESIS-0.080
- FATTY_ACID_METABOLISM-0.080
- MYOGENESIS-0.070
- XENOBIOTIC_METABOLISM-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR35579821 | — | E | 0.918 |
| 2 | TCGA-BH-A0B3-01A-11R-A056-07 | — | E | 0.892 |
| 3 | R398 | — | — | 0.885 |
| 4 | TCGA-OR-A5JB-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.877 |
| 5 | SRR1516055 | — | — | 0.875 |
| 6 | TCGA-BH-A1F6-01A-11R-A13Q-07 | — | E | 0.875 |
| 7 | TCGA-66-2755-01A-01R-0851-07 | — | cohortSQ1 | 0.872 |
| 8 | SRR1516056 | — | — | 0.872 |
| 9 | 6e639239-cdae-4412-880f-ef813a956ff7 | — | — | 0.870 |
| 10 | 20050099.TNBC | — | D | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |